Metabolic Syndrome and Antipsychotics: The Role of Mitochondrial Fission/Fusion Imbalance
Second-generation antipsychotics (SGAs) are known to increase cardiovascular risk through several physiological mechanisms, including insulin resistance, hepatic steatosis, hyperphagia, and accelerated weight gain. There are limited prophylactic interventions to prevent these side effects of SGAs, i...
Main Authors: | Andrea del Campo, Catalina Bustos, Carolina Mascayano, Claudio Acuña-Castillo, Rodrigo Troncoso, Leonel E. Rojo |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-04-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fendo.2018.00144/full |
Similar Items
-
Anthocyanins from <i>Aristotelia chilensis</i> Prevent Olanzapine-Induced Hepatic-Lipid Accumulation but Not Insulin Resistance in Skeletal Muscle Cells
by: Andrea del Campo, et al.
Published: (2021-10-01) -
Mifepristone for Treatment of Metabolic Syndrome: Beyond Cushing’s Syndrome
by: Francisco Díaz-Castro, et al.
Published: (2020-04-01) -
Antipsychotic use in a resource-limited setting: Findings in an Eastern Cape psychiatric hospital
by: Ingrid Eloff, et al.
Published: (2017-07-01) -
Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain
by: Diana Grajales, et al.
Published: (2019-10-01) -
The Effect of Long-Term Second-Generation Antipsychotics Use on the Metabolic Syndrome Parameters in Jordanian Population
by: Osama Abo Alrob, et al.
Published: (2019-06-01)